These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 550289

  • 1. [Susceptibility tests of Fonsecaea pedrosoi strains to the combination of thiabendazole and amphotericin B "in vitro"].
    deRosanda MA.
    Rev Inst Med Trop Sao Paulo; 1979; 21(6):347-9. PubMed ID: 550289
    [No Abstract] [Full Text] [Related]

  • 2. [Synergistic action of amphotericin B and 5-fluorocytosine on Fonsecaea pedrosoi].
    de Resende MA.
    Rev Inst Med Trop Sao Paulo; 1979; 21(6):344-6. PubMed ID: 550288
    [No Abstract] [Full Text] [Related]

  • 3. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.
    Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE.
    Mycoses; 2004 Jun; 47(5-6):216-21. PubMed ID: 15189187
    [Abstract] [Full Text] [Related]

  • 4. Fonsecaea pedrosoi: lipid composition and determination of susceptibility to amphotericin B.
    Gomes MH, Resende MA.
    Can J Microbiol; 1992 Mar; 38(3):209-14. PubMed ID: 1393822
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of chromomycosis with a combination of 5-fluorocytosine and thiabendazole. Apropos of a Zairian case due to Fonsecaea pedrosoi].
    De Clercq D, Kakiesse M, De Vroey C, Mazebo P.
    Ann Soc Belg Med Trop; 1985 Mar; 65(1):95-7. PubMed ID: 4004379
    [No Abstract] [Full Text] [Related]

  • 6. Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and itraconazole.
    Paniz-Mondolfi AE, Colella MT, Negrín DC, Aranzazu N, Oliver M, Reyes-Jaimes O, Pérez-Alvarez AM.
    Med Mycol; 2008 Mar; 46(2):179-84. PubMed ID: 18324498
    [Abstract] [Full Text] [Related]

  • 7. Phenotypic and molecular identification of Fonsecaea pedrosoi strains isolated from chromoblastomycosis patients in Mexico and Venezuela.
    Carolina Rojas O, León-Cachón RB, Pérez-Maya AA, Aguirre-Garza M, Moreno-Treviño MG, González GM.
    Mycoses; 2015 May; 58(5):267-72. PubMed ID: 25728464
    [Abstract] [Full Text] [Related]

  • 8. Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.
    Deng S, Lei W, de Hoog GS, Yang L, Vitale RG, Rafati H, Seyedmousavi M, Tolooe A, van der Lee H, Liao W, Verweij PE, Seyedmousavi S.
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581111
    [Abstract] [Full Text] [Related]

  • 9. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media].
    Tapia C, León E, Palavecino E.
    Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079
    [Abstract] [Full Text] [Related]

  • 10. A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine.
    Park SG, Oh SH, Suh SB, Lee KH, Chung KY.
    Br J Dermatol; 2005 Mar; 152(3):560-4. PubMed ID: 15787829
    [Abstract] [Full Text] [Related]

  • 11. In vitro antifungal activity of amphotericin B against Emmonsia crescens.
    Otcenásek M, Hubálek Z.
    Sabouraudia; 1968 Jun; 6(3):255-9. PubMed ID: 5692860
    [No Abstract] [Full Text] [Related]

  • 12. [In vitro antifungal susceptibility of dematiaceous filamentous fungi using the E-test].
    Vivas JR, Torres-Rodríguez JM.
    Rev Esp Quimioter; 2001 Jun; 14(2):191-7. PubMed ID: 11704774
    [Abstract] [Full Text] [Related]

  • 13. Development of strains of genus Candida and genus Torulopsis resistant to antimycotics.
    Bodenhoff J.
    Acta Pathol Microbiol Scand; 1969 Jun; 75(4):622-30. PubMed ID: 4315885
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of chromomycosis with oral high-dose amphotericin B.
    Iijima S, Takase T, Otsuka F.
    Arch Dermatol; 1995 Apr; 131(4):399-401. PubMed ID: 7726580
    [No Abstract] [Full Text] [Related]

  • 15. In vitro susceptibility testing of Fonsecaea pedrosoi to antifungals.
    de Bedout C, Gómez BL, Restrepo A.
    Rev Inst Med Trop Sao Paulo; 1997 Apr; 39(3):145-8. PubMed ID: 9460254
    [Abstract] [Full Text] [Related]

  • 16. Systemic (cerebral) chromoblastomycosis: diagnosis during life, drug sensitivities, and treatment of a single case.
    Summers DS.
    Neurology; 1968 Mar; 18(3):278. PubMed ID: 5690340
    [No Abstract] [Full Text] [Related]

  • 17. [On the sensitivity of some yeasts to nystatin and amphotericin B].
    Frágner P, Zajíková J.
    Cesk Epidemiol Mikrobiol Imunol; 1966 May; 15(3):185-90. PubMed ID: 4223604
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of Fonsecaea pedrosoi sclerotic cells obtained in vivo and in vitro: ultrastructure and antigenicity.
    da Silva JP, Alviano DS, Alviano CS, de Souza W, Travassos LR, Diniz JA, Rozental S.
    FEMS Immunol Med Microbiol; 2002 Mar 25; 33(1):63-9. PubMed ID: 11985971
    [Abstract] [Full Text] [Related]

  • 19. Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.
    Palmeira VF, Kneipp LF, Rozental S, Alviano CS, Santos AL.
    PLoS One; 2008 Mar 25; 3(10):e3382. PubMed ID: 18852883
    [Abstract] [Full Text] [Related]

  • 20. Effect of environmental factors on Fonsecaea pedrosoi morphogenesis with emphasis on sclerotic cells induced by propranolol.
    Alviano CS, Farbiarz SR, Travassos LR, Angluster J, de Souza W.
    Mycopathologia; 1992 Jul 25; 119(1):17-23. PubMed ID: 1406903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.